Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors
暂无分享,去创建一个
M. Robb | B. Gunn | G. Alter | N. Michael | Dohoon Kim | M. Eller | L. Hensley | R. Schoepp | L. Eller | D. Paquin-Proulx | Aljawharah Alrubayyi | D. Clark | Matthew Creegan | H. Kibuuka | M. Millard | S. Wakabi | M. Hepburn | M. Creegan | Dominic Paquin-Proulx
[1] D. Brodie,et al. Post-acute COVID-19 syndrome , 2021, Nature Medicine.
[2] David A. Drew,et al. Attributes and predictors of long COVID , 2021, Nature Medicine.
[3] P. Horby,et al. Ebola virus antibody decay–stimulation in a high proportion of survivors , 2021, Nature.
[4] Y. Kawaoka,et al. A Fc-Engineering Approach to Define Functional Humoral Correlates of Immunity Against Ebola Virus , 2020, SSRN Electronic Journal.
[5] P. Maes,et al. Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study , 2020, The Lancet Infectious Diseases.
[6] Anthony K. P. Jones,et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis. , 2020, Journal of rehabilitation medicine.
[7] Donald S. Grant,et al. Ebola-Specific CD8+ and CD4+ T Cell Responses in Sierra Leonean Ebola Virus Survivors with and without Post Viral Sequelae. , 2020, The Journal of infectious diseases.
[8] C. Levy-marchal,et al. Long-lasting severe immune dysfunction in Ebola virus disease survivors , 2019, Nature Communications.
[9] G. Firestein,et al. Chronic Joint Pain 3 Years after Chikungunya Virus Infection Largely Characterized by Relapsing-remitting Symptoms , 2019, The Journal of Rheumatology.
[10] J. Anaya,et al. Ebola virus disease: An emerging and re-emerging viral threat. , 2019, Journal of autoimmunity.
[11] Donald S. Grant,et al. Long-Term Complications of Ebola Virus Disease: Prevalence and Predictors of Major Symptoms and the Role of Inflammation. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] Tokiko Watanabe,et al. Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study , 2019, PLoS neglected tropical diseases.
[13] B. Gunn,et al. Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses , 2019, The Journal of infectious diseases.
[14] G. Alter,et al. A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation☆ , 2019, Journal of immunological methods.
[15] G. Alter,et al. A versatile high-throughput assay to characterize antibody-mediated neutrophil phagocytosis , 2019, Journal of immunological methods.
[16] J. Routy,et al. Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.
[17] Rodolphe Thiebaut,et al. Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[18] J. Dye,et al. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection , 2018, Cell.
[19] D. Lauffenburger,et al. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus. , 2018, Cell host & microbe.
[20] M. Pauly,et al. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates. , 2018, The Journal of infectious diseases.
[21] T. Monath,et al. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study. , 2018, The Lancet. Infectious diseases.
[22] M. Cranfield,et al. Suspected Exposure to Filoviruses Among People Contacting Wildlife in Southwestern Uganda. , 2018, The Journal of infectious diseases.
[23] Y. Sakurai,et al. Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates , 2018, The Journal of infectious diseases.
[24] Samantha E. Zak,et al. Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail , 2018, Viruses.
[25] J. Shiloach,et al. Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo , 2018, The Journal of infectious diseases.
[26] B. Nicholson,et al. Ebola Virus Neutralizing Antibodies Detectable in Survivors of theYambuku, Zaire Outbreak 40 Years after Infection , 2017, The Journal of infectious diseases.
[27] Dennis Andersson,et al. A retrospective cohort study , 2018 .
[28] M. Wang,et al. Antibody-dependent-cellular-cytotoxicity-inducing antibodies significantly affect the post-exposure treatment of Ebola virus infection , 2017, Scientific Reports.
[29] Sarah L. Keasey,et al. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses , 2016, Clinical and Vaccine Immunology.
[30] J. Mascola,et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody , 2016, Science.
[31] D. Burton,et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak , 2016, Science.
[32] G. Olinger,et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. , 2015, Lancet. Infectious Diseases (Print).
[33] Jay B. Varkey,et al. Human Ebola virus infection results in substantial immune activation , 2015, Proceedings of the National Academy of Sciences.
[34] J. M. Carter,et al. Multiplexed Microsphere Suspension Array-Based Immunoassays. , 2015, Methods in molecular biology.
[35] P. Roddy. A Call to Action to Enhance Filovirus Disease Outbreak Preparedness and Response , 2014, Viruses.
[36] K. Porten,et al. Emerging Filoviral Disease in Uganda: Proposed Explanations and Research Directions , 2014, The American journal of tropical medicine and hygiene.
[37] C. Bailey-Kellogg,et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. , 2012, Journal of immunological methods.
[38] H. Feldmann,et al. Ebola haemorrhagic fever , 2011, The Lancet.
[39] D. Irvine,et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. , 2010, Journal of immunological methods.
[40] M. Nanyunja,et al. Ebola Hemorrhagic Fever Associated with Novel Virus Strain, Uganda, 2007–2008 , 2010, Emerging infectious diseases.
[41] N. Wauquier,et al. High Prevalence of Both Humoral and Cellular Immunity to Zaire ebolavirus among Rural Populations in Gabon , 2010, PloS one.
[42] N. Sullivan,et al. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.
[43] W. Ian Lipkin,et al. Newly Discovered Ebola Virus Associated with Hemorrhagic Fever Outbreak in Uganda , 2008, PLoS pathogens.
[44] Pedagógia,et al. Cross Sectional Study , 2019 .
[45] M. Lederman,et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.
[46] J Bertolli,et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. , 1999, The Journal of infectious diseases.
[47] P. Rollin,et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. , 1999, The Journal of infectious diseases.